Observational Study of Acoramidis in Adults with Wild-Type or Variant Transthyretin Amyloid Cardiomyopathy
Led by Bayer · Updated on 2026-09-15
500
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Transthyretin amyloid cardiomyopathy ATTR-CM is a progressive heart condition caused by the buildup of an abnormal protein called transthyretin in the heart, which can impair heart function and worsen symptoms over time. Acoramidis is a medicine approved for adults with wild-type or hereditary ATTR-CM. While its benefits have been shown in clinical trials, more information is needed about how it is used and how patients fare in everyday medical care.
This observational study in France follows patients receiving acoramidis as part of their usual medical treatment. Participants take acoramidis orally at a dose of 712 mg twice daily. No experimental treatments or extra medical procedures are required beyond standard care. The study collects data directly from hospitals and from the Healthcare European Amyloidosis Registry to understand patient experiences and treatment use.
Participants will be followed for 12 months after starting acoramidis. During this time, researchers will assess quality of life, daily functioning, and overall well-being at 3, 6, 9, and 12 months using patient-completed questionnaires. Additional information about patient characteristics, treatment patterns, safety, and tolerability will also be collected. This research aims to improve understanding and care of people living with ATTR-CM.
CONDITIONS
Brief Title
Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy
Research Team
B
Bayer Clinical Trials Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Confirmed diagnosis of transthyretin amyloid cardiomyopathy with wild-type or variant transthyretin
Starting treatment with acoramidis as decided by the treating physician before enrollment
You will not qualify if you...
Any contraindications listed in the local approved product information for acoramidis
Previous treatment with disease-modifying therapies such as tafamidis or TTR silencers
Participation in other investigational trials involving new medicinal products or devices outside routine care
Under legal protection (guardianship, curatorship, or other legal measures) or deprived of liberty by legal decision at enrollment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote as per study protocol)
Treatment and Observation
Duration - 12 months
Participants receive acoramidis as part of their usual medical care and complete quality of life questionnaires at 3, 6, 9, and 12 months. Health data is collected from hospitals and a European amyloidosis registry.
Questionnaires at 4 time points during the year
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
ACO-REAL Observational Study Evaluating Acoramidis Use and Patient Outcomes in Transthyretin Amyloid Cardiomyopathy in Routine Practice
Observational Study of Acoramidis in Adults with Wild-Type or Variant Transthyretin Amyloid Cardiomyopathy
Thailand Registry for Transthyretin Amyloid Cardiomyopathy
Studying Symptoms, Heart Imaging, and Treatment Outcomes
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The Healthcare Amyloidosis European Registry (HEAR): design of a national registry with a European extension strategy, and foundation of the F-CRIN GRACE network.